FDA
-
-
-
-
-
-
-
Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results
-
-
-
-
-
-
-
FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency
-
-
-
-
-
-
-
Softlab9 Target Acquisition CleanGo GreenGo Signs Supply Agreement
-
-
-
-
-
-
-
Catalyst Biosciences Announces Pricing of Public Offering of Common Stock
-
-
-
-
-
-
-
Catalyst Biosciences Present at the Raymond James Human Health Innovation Conference
-
-
-
-
-
-
-
Catalyst Biosciences (CBIO) Reports Pivotal Phase 3 Study Design for MarzAA in Individuals with Hemophilia A or B with Inhibitors
-
-
-
-
-
-
-
Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

